knowledge -WSS

knowledge

author：leisure time 2025-09-27 22:59:59 - browse：9173

Micrograph of ulcerative colitis -- biotech coverage from STAT — Micrograph of chronic active ulcerative colitis in a biopsy specimen. Wikimedia Commons

Checkpoint inhibitors, drugs that unleash the immune system, have turned into blockbuster therapies that have transformed outcomes for some patients with deadly cancers. AltruBio, a Bay Area biotech, is betting it can help patients suffering from autoimmune and inflammatory diseases by taking the opposite tack: pumping the brakes on runaway immune responses.

The company on Tuesday announced that it has raised $225 million in a Series B venture round led by BVP Partners, with the biotech’s backers also including RA Capital Management, Cormorant Asset Management, and Soleus Capital. AltruBio plans to put that money toward advancing a drug that is already being tested in a mid-stage trial for ulcerative colitis, an increasingly competitive market in which a number of pharma companies have launched drugs.

It’s the latest example of intense investor interest in immunology-focused companies. Firms such as Paragon Therapeutics and Prometheus Laboratories have recently been at the center of financing mega-rounds, and Blackstone Life Sciences recently committed up to $300 million to launch Uniquity Bio, a company developing treatments for asthma and chronic obstructive pulmonary disease.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： Florida babysitter arrested over hot car death, authorities say

WSS

How housing is health care on Long Island

Telehealth for opioid use disorder is lifesaving

New Covid vaccine is recommended for everyone 6 months or older

How medical schools plan to diversify without affirmative action

Biden White House, tech companies launch new safeguards around emerging AI technology

Regeneron agrees to White House price limits on anti

entertainment

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Mega Millions jackpot grows to $720 million ahead of Friday's drawing

Medical leaders decry Supreme Court decision on affirmative action

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

In Memoriam: Notable people who died in 2023

A new deal aims to ramp up use of AI in rehab care decisions

In Memoriam: Notable people who died in 2023

Long Covid needs a new name — and a new frame

Trump demands the U.S. pay no more for drugs than other countries … again

Walmart eyes Medicare Advantage provider ChenMed

hotspot

EMA weighs against approval for Mirati's lung cancer drug

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

Private equity could exacerbate cardiology's overuse problem, experts fear

Pig kidney works a record two months in donated body

Pig kidney works a record two months in donated body

Regeneron agrees to White House price limits on anti

knowledge

focus

explore

Wikipedia